We have six issued US Patents and fourteen follow on patent applications pending in the US and internationally. These claim advances in linker technology, the use of cleavable linkers in soluble circulating  and solid supports, including hydrogels.  Certain applications have claims directed towards specific therapeutic applications and compositions of matter.  

May 16, 2017         9,649,385   Claims on biodegradable hydrogels

July 12, 2016         9,387,254   Claims on linkers

February 3, 2015    8,946,405   Claims on linkers on solid supports.
June 17, 2014        8,754,190   Claims on adapted linkers for non-amines.
April 22, 2014        8,703,907   Claims on dendrimers with releasable linkers.
March 25, 2014     8,680,315   Claims on linkers, soluble conjugates

Prolynx in the news

August 2018 ProLynx and Daiichi Sanko announce the development of technology for the half-life extension of small molecules in the eye

April 2018 ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer

April 2018 ProLynx extends lead in half-life extension platform technology-- Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
Sept 2017 ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists

June 2017 ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye

June 2017 ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

May 2017ProLynx issued US patent for cleavable linker technology on hydrogels

June 2015 ProLynx announces active IND of a novel ultra-long acting PEG-SN-38 conjugate to treat solid tumors
February 2015 ProLynx issued key patent for using releasable linkers on insoluble carriers    
November 2014 ProLynx awarded NSF Phase II grant for hydrogel platform research and development

August 2014 ProLynx enters funded evaluation agreement with GlaxoSmithKline Research & Development Limited (GSK)
June 2014 ProLynx granted US Patent 8,754,190 covering clinical candidate PEG-SN38
May 2014 ProLynx & RxGen publish data on ocular delivery platform at ARVO 2014 Annual Meeting
April 2014 US Patent 8,703,907 on controlled release from dendrimers
March 2014 Publication in JMedChem relating to PEG-SN-38 conjugates with ultra-long half life, low Cmax, and low glucuronide formation; Japanese partner advances toward Phase I trials. 
March 2014 US Patent 8,680,315 on Beta-Eliminative Linkers
September 2012 Bayer Healthcare CoLaborator
April 2012 BioCentury